Navigation Links
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Date:8/19/2007

- Top Line Results Expected to Be Reported in 4Q 2007 -

LA JOLLA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has completed enrollment in its Phase IIb clinical trial of tezampanel for the treatment of acute migraine headache. Tezampanel is an AMPA/kainate (AK) receptor antagonist that offers a non-opioid, non-vascular and non-serotonergic approach to the management of pain and represents a potentially new and promising alternative to current migraine treatments.

The clinical trial is a double-blind, placebo-controlled, multi-center trial that reached its targeted enrollment of 300 patients suffering a single migraine attack, with or without aura. Patients are randomized to one of four arms and receive a 40 mg, 70 mg, or 100 mg single, subcutaneous dose of tezampanel or placebo. The purpose of the trial is to identify a dose, or a range of doses, that could be used in a Phase III development program for tezampanel in acute migraine. The primary efficacy endpoint for the trial is headache pain relief at two hours post-dose. Secondary efficacy endpoints include pain free status at two hours, sustained pain relief and sustained pain free at 24 hours, and headache recurrence and relapse. Additional measures include assessments of functional disability and patient satisfaction, relief of migraine-associated symptoms such as nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound), as well as various assessments that characterize speed of treatment onset. Safety, tolerability and plasma pharmacokinetic data will also be evaluated.

"Completing enrollment in our Phase IIb trial with tezampanel is an i
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
(Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
(Date:9/1/2015)... , ... September 01, 2015 , ... Royal River Natural ... study that followed men and women for 19 years and found that, among those ... not take multivitamins. , The report is part of the September 2015 issue of ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Two of Washington ... cultural relations through food and dining. , Recently named “the next big thing” ... Diotaiuti are known for telling the whole story behind food and reclaiming culinary traditions ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, tax, ... named a “Best of the Best” firm in the U.S., as well as being ... of the Best” in the U.S., selected exclusively on performance in specific areas of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Kit is now available. With the Connectivity Kit, EasySampler data is ... jacketed lab reactor control experiment, on a touchscreen platform. , EasySampler fully ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... Northeast, and boys are at higher risk than girls, study ... sweeping government study of childhood cancers has found numerous differences ... and where he or she lives in the United States. ... cancers, the researchers found, and youngsters in the Northeast were ...
... June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) ... its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with cytarabine ... had been presented at the 44th Annual Meeting of,the ... The Phase III trial started in March 2005 ...
... (ASCO) ... Annual Meeting -, IRVINE, Calif., June 2 ... an analysis from the,Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The results,suggest ... reduction in the risk of death in newly diagnosed,patients with metastatic osteosarcoma, ...
... Marketing and, Communications Professionals for Inspiring Tales of Patient and ... ... EL SEGUNDO, Calif., June 2 DaVita Inc., a leading,provider ... failure (CKD), today announced that the company,s internal,publication, DaVita Magazine: Stories ...
... BETHESDA, Md., June 2 /Xinhua-PRNewswire/ -- Chindex ... Western healthcare,services and products in the People,s ... division, United Family Healthcare (UFH), responded to,the ... personnel,and other in- kind donations., Roberta ...
... the overall rate of high school baseball-related injuries has ... injuries that occur has increased, according to a new ... Research and Policy (CIRP) of The Research Institute at ... estimated 132,000 high school baseball-related injuries occurred with an ...
Cached Medicine News:Health News:U.S. Childhood Cancers Vary by Sex, Region 2Health News:U.S. Childhood Cancers Vary by Sex, Region 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 2Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 3Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 5Health News:DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 3Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 4Health News:Injuries to high school baseball players becoming more serious 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: